PASGHealthcare · BiotechnologyThe 3 Wall Street analysts covering Passage Bio, Inc. hold a median 12-month price target of $16 — +273.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 13 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Passage Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (89): Smaller than most of the companies we track.
Momentum (9): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PASG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +273.0% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Apr 2026 | Chardan Capital | Downgrade | Neutral | $21 → $7.00 |
| 21 Apr 2026 | Oppenheimer | Maintains | Outperform | $30 → $15 |
| 21 Apr 2026 | TD Cowen | Downgrade | Hold | — |
| 21 Apr 2026 | Wedbush | Downgrade | Neutral | $32 → $8.00 |
| 31 Mar 2026 | Oppenheimer | Initiates | Outperform | — |
| 4 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 12 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 14 Aug 2025 | Canaccord Genuity | Maintains | Buy | — |
| 14 Aug 2025 | Guggenheim | Maintains | Buy | — |
| 13 Aug 2025 | Wedbush | Maintains | Outperform | — |
| 24 June 2025 | Chardan Capital | Maintains | Buy | — |
| 4 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 29 Nov 2024 | Wedbush | Assumes | Outperform | $4.00 |
| 14 Nov 2024 | Canaccord Genuity | Maintains | Buy | — |
| 14 Nov 2024 | Chardan Capital | Maintains | Buy | — |
| 17 Sept 2024 | Canaccord Genuity | Reiterates | Buy | — |
| 3 Sept 2024 | Rodman & Renshaw | Initiates | Buy | — |
| 15 May 2024 | Canaccord Genuity | Maintains | Buy | — |
| 5 Mar 2024 | Canaccord Genuity | Reiterates | Buy | — |
| 14 Nov 2023 | Raymond James | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PASG appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Nov 2026, Passage Bio, Inc. returned −51.3% against +13.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 74% of US stocks
Cheaper than 78% of US stocks
Cheaper than 61% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 8% of US stocks
Higher than 9% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Passage Bio, Inc. has a market value of $13.7M and an enterprise value of −$6.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$36.1M.
Free cash flow in the twelve months to 30 June 2026: −$33.5M.
Trailing P/E: 0.0×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Passage Bio, Inc. employs 24 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Passage Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Halper Sadeh LLC is investigating the proposed merger of Passage Bio and Remix Therapeutics. If the transaction closes, Passage Bio shareholders are expected to own approximately 7% of the combined company.
Why it matters — The investigation and expected ownership share may be relevant to PASG shareholders assessing the proposed merger.
The 3 Wall Street analysts covering Passage Bio, Inc. have a median 12-month price target of $16, with estimates ranging from $8 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Passage Bio, Inc., 1 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Passage Bio, Inc. 55 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Nov 2026, Passage Bio, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +273.0% from the last close, and Ticker Nerd's factor model ranks Passage Bio, Inc. 55 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Passage Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PASG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $23 over the next 12 months.
Passage Bio, Inc. returned -51.3% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Passage Bio Inc. is a clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases.
The most recent item we track (Business Wire, 21 Oct 2026): "PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders". Halper Sadeh LLC is investigating the proposed merger of Passage Bio and Remix Therapeutics. If the transaction closes, Passage Bio shareholders are expected to own approximately 7% of the combined company.
Passage Bio Inc. is a clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases. Its current programs target rare, monogenic disorders of the central nervous system, with lead efforts centered on elevating progranulin levels and addressing underlying disease biology. The company’s pipeline includes clinical and early-stage candidates for conditions such as frontotemporal dementia, GM1 gangliosidosis, Krabbe disease, and other severe neurological disorders with limited treatment options. Passage Bio Inc. works in gene delivery and translational research to advance therapies designed for precise genetic correction or replacement within the brain and nervous system. Headquartered in Philadelphia, Pennsylvania, the company operates as a focused biotechnology developer within the genetic medicines field.
CEO Dr. William Chou M.D., Ph.D. · 24 employees · United States · https://www.passagebio.com
